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Background: In BRCA2 mutation carriers, increased risks
have been reported for several cancer sites besides breast
and ovary. As most of the families included in earlier reports
were selected on the basis of multiple breast/ovarian cancer
cases, it is possible that risk estimates may differ in mutation
carriers with a less striking family history.
Methods: In the Netherlands, 139 BRCA2 families with 66
different pathogenic mutations were included in a nationwide
study. To avoid testing bias, we chose not to estimate risk in
typed carriers, but rather in male and female family members
with a 50% prior probability of being a carrier (n = 1811).
The relative risk (RR) for each cancer site with the exception of
breast and ovarian cancer was determined by comparing
observed numbers with those expected, based on Dutch
cancer incidence rates.
Results: We observed an excess risk for four cancer sites:
pancreas (RR 5.9; 95% confidence interval (CI) 3.2 to 10.0),
prostate (2.5; 1.6 to 3.8), bone (14.4; 2.9 to 42.1) and
pharynx (7.3; 2.0 to 18.6). A small increase was observed
for cancer of the digestive tract (1.5; 1.1 to 1.9). Histological
verification was available for 46% of the tumours. Nearly all
increased risks reached statistical significance for men only.
Cancer risks tended to be higher for people before the age of
65 years. Moreover, families with mutations outside the
previously defined ovarian cancer cluster region tended to
have a higher cancer risk.
Conclusions: We found that BRCA2 carriers are at increased
risk for cancers of the prostate and pancreas, and possibly
bone and pharynx. Larger databases with extended follow
up are needed to provide insight into mutation specific risks
of selected carriers in BRCA2 families.
S
ince the identification of BRCA2,1 a tumour suppressor
gene associated with elevated risks for breast and
ovarian cancer, several studies have published pene-
trance analyses. The estimated cumulative risk of breast
cancer by the age of 70 years varies between 26% and 84% for
BRCA2 mutation carriers.2–7
In contrast with the uniformly high breast cancer risks
observed for both BRCA1 and BRCA2, significant differences
between the two genes have been reported regarding the risk
of other cancers. The ovarian cancer risk for a BRCA2 carrier
by the age of 70 years varies between 11% and 27%, in
comparison with clearly higher risks of 16–60% for a BRCA1
carrier.2 4 6–8 Male breast cancer is a characteristic element of
the BRCA2 phenotype. The estimated cumulative risk for a
male carrier by 80 years of age is 7%.4
Although cancer risks at sites other than breast and ovary
have only been investigated in a few studies, the increased
risks for these in BRCA2 carriers seem to be more pronounced
than in BRCA1 carriers.9–11 This may imply that BRCA2 is
involved in the pathogenesis of several types of cancers. A
study by the Breast Cancer Linkage Consortium (BCLC)
examined a variety of cancers in a series of 173 families
collected from 20 different centres in Europe, the USA and
Canada.9 They found a statistically significant excess risk of
prostate cancer (RR 4.65), pancreatic cancer (3.51), gallblad-
der and bile duct cancer (4.97), stomach cancer (2.59), and
malignant melanoma (2.58). Other studies have shown that
mutations located in the central region of the BRCA2 gene,
known as the ovarian cancer cluster region (OCCR), coincide
with an increased risk for ovarian cancer and a decreased risk
for breast cancer. In these families, there was some evidence
of a lower risk for prostate cancer (RR 0.52) in comparison
with the non-OCCR region, but no evidence for a difference
in breast cancer risk in men.4 12
As most of the families included in the BCLC study were
selected on the basis of multiple breast/ovarian cancer cases,
it is possible that cancer risk estimates for other sites may
differ in mutation carriers with a less striking family history.
To examine cancer risks in BRCA2 families in a less selected
setting, a nationwide database of breast/ovarian cancer
families was established in the Netherlands, comprising
more than 700 BRCA1/2 families to date. For the present
study, 139 BRCA2 families were selected, and cancer risks for
sites other than breast and ovary were estimated in
comparison with background rates in the general population.
Retrospective studies of penetrance for BRCA1 and BRCA2
have been criticised because they may be subject to several
types of bias, such as testing bias.13 14 Studies that primarily
used information of individuals in BRCA1/2 families who
were genotyped carriers could produce an overestimation of
cancer risks if affected family members were more inclined to
go for testing than non-affected relatives. To minimise testing
bias as much as possible, we used a novel approach for
selecting a study cohort of family members with a 50% prior
probability of being a carrier.
METHODS
The present study is part of an ongoing nationwide study in
the Netherlands on risk assessment and gene–environment
interactions in breast and/or ovarian cancer families (the
GEO-HEBON study). The general design involves a retro-
spective cohort study of members of all breast and/or ovarian
cancer families who were tested for BRCA1/2 mutations after
genetic counselling. The nationally agreed criteria for DNA
testing in breast and/or ovarian cancer families are rather
broad, implying that moderately high risk families are also
included in our cohort. Families were tested for BRCA1/2 in
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cases of clinically presumed hereditary breast and/or ovarian
cancer, when the mutation detection rate is about 10%15 (for
example, two breast cancer cases with one case before
50 years of age, .3 first degree relatives in two successive
generations with breast cancer before 60 years of age, breast
and/or ovarian cancer families), or if breast cancer was
diagnosed at a relatively young age (one patient ,35 years of
age). The GEO-HEBON study was approved by the medical
ethics committees of all participating centres.
The HEBON cohort
In each centre, pedigrees were drawn for all families who had
tested positive for BRCA2. These pedigrees were electronically
transferred to a local HEBON database. Information on dates
of birth (and death where applicable), date of first counsel-
ling and of last contact, dates of diagnosis and topography of
all cancers, prophylactic surgery, and mutation status was
collected from the medical records of each genetic centre.
Subsequently, the local databases were pooled to create a
nationwide HEBON database. In a small and densely
populated country such as the Netherlands, overlap between
families from different centres is likely, therefore, individuals
from all eligible families were linked by birth date, type of
mutation, first four letters of surname, and pedigree
structure. In this way, nine partly overlapping families were
combined before the HEBON cohort was established.
Families were eligible for the present study if one or more
individuals tested positive for a pathogenic BRCA2 mutation.
From 1998 to 2003, 139 families were ascertained from eight
clinical genetic centres in the Netherlands (Erasmus Medical
Center, Rotterdam (n=50), University Medical Center,
Nijmegen (n=19), Leiden University Medical Center
(n=15), Netherlands Cancer Institute (n=13), University
Medical Center, Utrecht (n=11), VU University Medical
Center, Amsterdam (n=10), University Medical Center,
Maastricht (n=9,) and the Netherlands Foundation for the
Detection of Hereditary Tumours (n=12)).
To draw an informative pedigree, non-informative
branches should be omitted. Segregation of the mutation
was inferred on clinical grounds following the rules of
autosomal dominant inheritance of breast cancer. If, how-
ever, the probability of paternal and maternal inheritance
was equally likely, then mutation testing or clinical informa-
tion (for example, breast cancer before 50 years of age and/or
ovarian cancer at any age) was used to make decisions
regarding the informative pedigree branches. Selection of the
HEBON cohort was halted if paternal or maternal inheritance
of the mutation could no longer be established.
The 139 families comprised 5957 individuals, after exclu-
sion of partners and individuals with unknown gender
(n=265). This overall cohort of 5957 individuals consisted
of a total of 2741 men (46%) and 3216 women (54%),
including 414 typed carriers and 324 typed non-carriers. The
families comprised 85 hereditary breast cancer families, 52
hereditary breast and ovarian cancer families, and 2 ovarian
cancer only families. A family history with 1 case of breast
cancer was reported by 12 families, 2 cases in 31 histories, 3
cases in 34 histories, 4–5 cases in 37 histories, and 6 or more
cases in 23 histories.
Selection of family members into the analysed cohort
The principal aim of the study was to estimate cancer risks in
BRCA2 families for sites other than breast and ovary. Because
we used a retrospective design, we were concerned that
affected individuals might have been inclined to opt for DNA
testing more often than their non-affected relatives, which
would lead to overestimation of cancer risk in typed carriers.
Therefore, to minimise testing bias as much as possible, we
used a novel approach for selecting a study cohort of family
members with a 50% prior probability of being a carrier,
irrespective of their known carrier status. We selected our
study cohort as indicated in fig 1. Firstly, in each family the
youngest typed carrier was identified by the most recent date
of birth. This mutation carrier and all his/her first degree
relatives (including parents) were selected into the cohort.
Subsequently, the grandparents and siblings of both preced-
ing generations of the typed carrier were selected. Thus, the
analysed cohort definition was not based on typed carriers,
except for the identification of the youngest carrier, but on at
least a 50% prior probability of being a carrier.
Initially, the cohort thus selected consisted of 2101 family
members. To estimate cancer risks, we only included
individuals who were alive and free of cancer in 1960, or
who were born after 1960. We chose 1960 as the start of
follow up, because reliable cancer incidence rates needed for
the calculation of expected numbers of cancer are only
available for the Netherlands from this year onwards. In
addition, misclassification of cancer diagnoses prior to 1960,
as retrospectively reported by family members, is much more
likely. We also excluded all individuals born before 1 January
1880. After excluding 290 individuals without follow up in
the relevant calendar period, the analysed cohort of 50%
presumed carriers comprised 1811 individuals from 139
BRCA2 families, including 1008 women (56%) and 803 men
(44%).
Cancers other than breast and ovary
All cancers were coded according to the International
Classification of Diseases, revision 9.16 We attempted to
confirm all cancer diagnoses at sites other than breast and
ovary, which were mentioned during genetic counselling
either by the individuals concerned or by their family
members. Initially, cancer diagnoses were medically and/or
pathologically confirmed by pathology reports and clinical
records. Furthermore, linkage with the Dutch Network and
National Database for Pathology (PALGA) was performed
especially for this analysis.
Statistical analyses
Standard methods for analysis of retrospective cohort studies
were used.17 For all individuals without breast or ovarian
cancer, follow up started on 1 January 1960 or date of birth,
whichever occurred later, and ended at the date of first
cancer diagnosis, date of death, date of last contact, or last
DNA test in the family, or at the age of 80 years, whichever
occurred first. For individuals with breast or ovarian cancer
as their first cancer diagnosis, follow up started from the date
of diagnosis of this cancer or on 1 January 1960, whichever
occurred later. End of follow up was defined similarly as for
the rest of the cohort, except that it was stopped on the date
of diagnosis of a second cancer at a site other than breast or
ovary.
As 33% of the exact birth dates were missing, we imputed
unknown birth dates based on the known birth dates in each
generation of the family and the pedigree structure. The
procedure of imputing missing dates was as follows. Known
birth dates were used to estimate the mean birth date in each
kinship, and this value was assigned to siblings with
unknown birth dates (horizontal imputing). Subsequently,
birth cohorts were defined, and the average age difference
between generations within each family for each birth cohort
was calculated. This estimate of the age difference between
generations was then used for vertical imputing of birth dates
of (a) children, or (b) parents in cases where their birth dates
and those of each of their siblings were unknown. Depending
on the complexity of the family structure, family size, and the
percentage of missing data, one or more iterations were
carried out to assign the best possible estimates of birth dates
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to individuals with missing birth dates. Firstly, families with
more than 80% known birth dates were selected, then birth
dates of a random selection of 70% family members were
defined as missing. Subsequently, the missing birth dates
were imputed as described above. Both the absolute and
mean deviance between exact and imputed dates was
calculated. For 80% of the imputed dates, accuracy within
5 years could be accomplished (data not shown). In total,
birth dates of 600 individuals in the analysed cohort (33%)
were imputed. Missing dates of diagnosis for individuals who
died from cancer at a known site with a known date of death
were estimated from sex, calendar period, and site specific
median survival rates in the general population derived from
the Netherlands Cancer Registries and the Comprehensive
Cancer Centre South.18 19 In addition, site specific mean ages
at diagnosis of cancer in the general population were used to
assign values to missing dates of diagnosis of affected
individuals who did not die from cancer, based on data of
the Comprehensive Cancer Centre Amsterdam and the
Netherlands Cancer Registries.18 In this way, date at
diagnosis was imputed for 126 affected individuals (63%).
Cancer risk in the BRCA2 family members relative to the
risk in the general population (relative risk; RR) was
evaluated with the standardised incidence ratio, which is
the ratio of observed to expected cases in the cohort.17 The
expected number of cases was calculated by multiplying
person years at risk by the age, sex, calendar period, and site
specific cancer incidence rates in the general population, with
the use of a bespoke computer program developed in the
Netherlands Cancer Institute.20 Relevant incidence rates were
obtained from the Eindhoven Cancer Registry to 1990 and
from the Netherlands Cancer Registry from 1990
onwards.18 19 21
By selection, members of the analysed cohort had a 50%
probability of being a carrier. Estimates of RR were obtained
in two ways. Firstly, RRs of each cancer type among carriers
were directly derived from 50% presumed carriers according
to the formula RRcarriers = (26(RR50%carriers21)+1. However,
during follow up, carriers were censored more frequently
than non-carriers, and died on average earlier than the non-
carriers. Therefore, we calculated the RR for carriers by a
specific method (see Appendix).
The estimates from the two methods turned out to be very
similar (data not shown). Except for the overall risk
estimates and those according to gender, all stratified
analyses were based on the first method.
Two sided statistical significance levels for the RRs were
estimated, and 95% confidence intervals (CI) calculated
under Poisson distribution of the observed frequencies. RR
analyses were performed for each individual cancer site and
for major cancer diagnostic categories: cancer of mouth and
pharynx (ICD 140–149), gastrointestinal tract (ICD 150–159),
urogenital tract (ICD 180–189), and leukaemia (ICD 200–
208).
Additional stratified analyses were performed for ages
below and above 65 years. Because the mean age at diagnosis
for prostate cancer in the population is 73 years, the stratified
analysis for this cancer used this as the cutoff point. To
evaluate the differences in cancer risks for sites other than
breast and ovary between families with mutations inside the
OCCR and families with mutations outside this region, we
used the definition of the OCCR as originally reported by
Gayther et al, with nucleotide boundaries between 3035 and
6629.12 Second primary or third non-breast/ovarian malig-
nancies were excluded from the main analyses.
Risks may be overestimated if families are referred for
counselling on the basis of occurrence of other cancers than
breast and ovary. Therefore, analyses stratified on numbers of
breast and ovarian cancers in each family were performed to
examine possible ascertainment bias. We assumed that
referral bias would be more likely in families with a weaker
family history of breast and/or ovarian cancer. Families with
three or more breast cancers before the age of 60 years, or
with any ovarian or male breast cancer were referred to as
families with a strong family history (84/139; 60%) and those
with fewer than three such individuals as families with a
weaker family history (56/139; 40%).
Finally, gender specific cumulative risks and corresponding
confidence intervals for cancers other than breast and ovary
by age t were estimated in terms of a Poisson distribution
using the following standard formula:
where F(t) is the cumulative risk by age t, l(j) is the gender
specific RR of cancer, and m(j) is the gender specific incidence
rate of cancer from 1989 in the Netherlands at age j. The
SPSS package (version 11.1; SPSS, Chicago, IL, USA) was
used for statistical analyses.
RESULTS
The analysed cohort of 50% presumed carriers comprised
1811 individuals from 139 BRCA2 families, including 1008
women (56%) and 803 men (44%). Table 1 provides general
characteristics of the analysed cohort.
Within the analysed cohort, 441 individuals had been
tested for BRCA2, of whom 303 (69%) were identified as
BRCA2 mutation carriers. Of these carriers, 158 (52%) people
were affected with a total of 168 cancers—that is, 110 breast
cancers, 19 ovarian cancers, 18 breast plus ovarian cancers
+
B35
B68
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– + – –
Figure 1 Selection of the analysed
cohort. The youngest mutation carrier in
the family (black, indicated by arrow)
and the selected cohort of family
members with a 50% prior probability
of being a carrier, irrespective of their
carrier status (grey): siblings of the
index person, and the ancestors and
their siblings.
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and 21 cancers other than breast and ovary. Of the 138
established non-carriers, 18 (13%) were affected with cancer.
Among the non-carriers, eight breast cancers, one ovarian
cancer, and nine cancers at sites other than breast and ovary
were observed in the analysed cohort. Of the 199 cancers at
sites other than breast and ovary, 183 occurred at known
sites. For 85 of these tumours (46%), pathology reports and
medical confirmation were available.
A total of 66 distinct pathogenic mutations were detected
in 139 families: 53 frameshift, 10 nonsense, and 3 splice site
mutations. Three mutations accounted for 64% of families:
6503delTT (24 families), 6174delT (9), and S1882X (9). All
other mutations occurred in four or fewer families. There
were 199 cancers reported at sites other than breast and ovary
of which 181 cancer sites were known, and for 85 (46%) of
these tumours, pathology reports and medical confirmation
were available.
The observed and expected numbers of cancers other than
breast and ovary in the analysed cohort, together with the
estimated RR, 95% CI and number of cancers confirmed by
pathology report are given in table 2. Overall, no significantly
increased risk was observed. However, for several sites
significantly increased risks were seen, such as for cancers
of the prostate (RR 2.5; 95% CI 1.6 to 3.8), pancreas (5.9; 3.2
to 10.0), pharynx (7.3; 2.0 to 18.6), liver (10.9; 3.5 to 25.4),
bone (14.4; 2.9 to 42.1), brain 3.9; 1.2 to 9.0), and digestive
system (1.5; 1.1 to 1.9).
As the liver is a common site for metastasis of breast/
ovarian cancer, it is of concern that only two liver cancers
were pathologically confirmed. This was also noted for bone
cancer, with one confirmed case. No increased risks were
observed for cancers of the lung (RR 0.4; 95% CI 0.3 to 0.6),
bladder (1.2; 0.5 to 2.3), stomach(1.2; 0.6 to 2.0), colon (1.5;
0.9 to 2.3), and larynx (1.2; 0.2 to 3.6), cutaneous melanoma
(0.1; 0.01 to 0.2), and cancer of the bile duct (only one
observed case).
Pathological confirmation was available for seven of 14
pancreatic cancers. These tumours were diagnosed at ages of
between 9 and 71 years (median 64). The tumour diagnosed
in a 9 year old girl was pathologically confirmed as a tumour
in the head of the pancreas. Three bone tumours were seen,
of which one was pathologically confirmed as an osteosar-
coma in a 14 year old boy. These bone tumours were
diagnosed at 14, 42, and 50 years (median 61, mean 56).
The 24 cases of prostate cancer in our analysed cohort were
diagnosed in 20 families; seven cases were pathologically
confirmed. Their ages at diagnoses varied between 50 and
74 years (median age 73, mean 69).
Table 3 gives gender specific risk estimates for sites other
than breast and ovary. Among male family members, besides
the increased risks described in table 2, an elevated risk was
also found for cancers of the urogenital system (ICD 179–189:
RR 1.7; 95% CI 1.2 to 2.4), which can be explained by the
inclusion of prostate cancer in this major cancer diagnostic
category. For female subjects, however, the overall risk for
sites other than breast/ovary appeared to be decreased (RR
0.3; 95% CI 0.3–0.4), and only a marginally significantly
increased site specific risk for pancreatic cancer 3.7; 1.0–9.4)
was found.
Table 4 shows that the RR estimates for BRCA2 mutation
carriers were in general greater for those younger than
65 years of age than for those aged 65 years and older (RR
5.5; 95% CI 0.7 to 1.4 v 0.2; 0.2 to 0.3, p for difference
,0.001). Site specific cancer risks for carriers younger than
65 years, or 73 years in case of prostate cancer, were higher
for cancer of the pancreas (37.1; CI 16.0 to 73.1), pharynx
(15.7; 1.8 to 56.6), and prostate (8.0; 4.1 to 14.0).
Furthermore, a significantly increased RR was observed for
colon cancer before the age of 65 years (8.0; 3.4 to 15.7). For
those aged 65 years and older, a significant increase was only
observed for pancreatic cancer (2.5; 1.0 to 5.2).
In our series, a total of 92 families (66%) had mutations
inside the OCCR region and 47 families (34%) had mutations
outside the OCCR region. In table 5, the observed risks for
cancers sites other than breast and ovary are compared
between families with mutations inside the OCCR region and
families with mutations outside this region. Prostate cancer
risk in families with mutations inside the OCCR region
appeared to be lower than for other mutations elsewhere in
the gene (RR 2.0: 95% C.I. 1.1 to 3.4 v 3.6; 1.7 to 6.6). This
was also observed for pancreatic cancer (4.4: 1.9 to 8.7 v 8.9;
3.6 to 18.3). These observed reduced cancer risks were,
however, not statistically significant (p=0.12 for both
cancers).
Estimated cumulative risks for prostate and pancreas
cancer are shown in table 6. For pancreatic cancer the
estimated cumulative risks by the age of 80 years for male
subjects was 6.9% (95% CI 3.8 to 10.0) and for female
subjects 2.8% (0.9 to 4.7). The estimated cumulative risk for
prostate cancer up to the age of 80 years was 17.3% (12.5 to
22.0).
DISCUSSION
This study provides strong confirmation of increased risks for
prostate cancer and pancreatic cancer in families with a
pathogenic BRCA2 mutation. There is also a suggestion of
increased risks for pharyngeal and bone cancer, but the
confidence intervals of these latter risks were rather wide. In
addition, a slightly increased risk for cancers of the digestive
tract was observed. For all these cancers, RR appeared to be
more strongly increased at an earlier age. These risk
elevations particularly concerned male subjects.
Because of the way our analysed cohort was selected,
testing bias was excluded. However, we realise that our
approach could not fully eliminate ascertainment bias
because the non-breast/ovary cancer events observed in these
families may have contributed to the decision to opt for DNA
testing, and consequently to ascertainment bias.
The increased risk for prostate cancer in BRCA2 families
had been observed in several earlier studies. The elevated RR
found in the BCLC study was based on a total of 69 observed
prostate cancer cases among both probable carriers and a
group of individuals with unknown status (RR 4.65; 95% CI
3.48 to 6.22).9 An Icelandic study concerning families positive
for the BRCA2 999del5 mutation observed 34 prostate cancer
cases (4.79; 3.27 to 6.32).22 In our study, the observed
increased risk for prostate cancer, based on 24 cases, is
slightly lower (2.5; 1.6 to 3.8).
The contribution of BRCA2 mutations to early onset
prostate cancer has also been investigated in a series of 263
Table 1 General characteristics of analysed cohort of
Dutch BRCA2 family members
Male Female Total
Total no. 803 1008 1811
Total number of person years 23 106 23 086 46 192
Number of people with:
Breast cancer 13 294 307
Ovarian cancer – 46 46
Breast and ovarian cancer – 24 24
Total breast/ovarian
cancer
13 364 377
Other cancer after breast/
ovarian
3 22 25
Other cancer (known
ICD-9 code)
139 (130) 60 (54) 199 (184)
PA confirmed* (%) 55 (42%) 28 (52%) 85 (46%)
*Confirmed by pathology report or clinical records.
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men diagnosed with the disease before 55 years, who were
unselected for family history.23 There are conflicting data
about the magnitude of the risk of prostate cancer among
Ashkenazi Jewish carriers of the common 6174del mutation,
which is located inside this OCCR.8 24–28 It was suggested that
the location of this latter mutation inside the OCCR region
might explain a decreased risk for prostate cancer.8 23 In our
series, 58% of prostate cancers occurred in families with
mutations inside the OCCR region. In agreement with the
literature, we observed for these families a lower risk for
prostate cancer (RR 2.0; 95% CI 1.1 to 3.4), while families
with BRCA2 mutations outside the OCCR region had a higher
risk (3.6; 1.7 to 6.6) than families with mutations inside this
region, although not significantly so.
However, when interpreting the overall increased risk of
prostate cancer in our study, it must be taken into account
that some of the observed prostate cancers may have been
detected during surveillance, as male members of BRCA2
mutation families may be more aware of possibly increased
cancer risks and may tend to ask for prostate cancer
screening more often than the general population. To
examine potential detection bias, the standardised mortality
ratio (SMR) of prostate cancer in BRCA2 families compared
with the general population was estimated. Of the 24 male
individuals diagnosed with prostate cancer in our cohort, 11
had died. Assuming that all deaths were due to prostate
cancer, the SMR for prostate cancer was estimated to be 2.5
(95% CI 1.2 to 4.4). As only some of the deaths will have been
Table 2 Cancer risks for sites other than breast and ovary in BRCA2 mutation carriers
ICD code Location Obs Exp RR 95% CI Pa (n)
– All 199 199.9 1 0.9 to 1.1 85
140–149 Buccal cavity and pharynx 6 3.6 2.4 0.9 to 5.3 4
141 Tongue 1 0.6 2.4 0.03 to 13.1 1
142 Salivary glands 1 0.4 4.6 0.1 to 25.4 1
143–145 Mouth 0 0.9 – – –
146–149 Pharynx 4 1.0 7.3 2.0 to 18.6 2
150–159 Digestive system 60 50.1 1.5 1.1 to 1.9 25
150 Oesophagus 1 2.0 – – –
151 Stomach 13 12.1 1.2 0.6 to 2.0 2
152 Small intestine 1 0.5 3.7 0.05 to 20.6 –
153 Colon 20 16.5 1.5 0.9 to 2.3 11
154 Rectum 3 10.8 – – 2
153–154 Colon/rectum 23 27.2 0.7 0.4 to 1.0 13
155 Liver 5 0.9 10.9 3.5 to 25.4 2
156 Gallbladder and extrahepatic bile
duct
1 2.8 – – 1
157 Pancreas 14 4.4 5.9 3.2 to 10.0 7
160–165 Respiratory system 35 44.3 0.5 0.4 to 0.8 13
160 Nasal cavaties 0 0.4 – – –
161 Larynx 3 2.7 1.2 0.2 to 3.6 2
162 Lung 30 40.4 0.4 0.3 to 0.6 9
163 Pleura/mesothelium 0 0.6 – – –
170 Bones 3 0.4 14.4 2.9 to 42.1 1
171 Connective tissues 1 1.1 0.8 0.01 to 4.6 1
172 Melanoma 2 3.5 0.1 0.01 to 0.2 1
179–189 Urogenital system 43 40.5 1.2 0.8 to 1.6 20
180 Cervix uteri 1 2.5 – – 1
182 Corpus uteri 6 4.4 1.8 0.7 to 3.9 3
185 Prostate gland 24 13.6 2.5 1.6 to 3.8 7
186 Testis 0 0.8 – – –
187 Penis 0 0.3 – – –
188 Bladder 9 8.4 1.2 0.5 to 2.3 6
189 Kidney 3 5.2 0.1 0.02 to 0.2 3
191 Brain 5 2.2 3.9 1.2 to 9.0 1
192 Thyroid gland 1 0.9 1.1 0.01 to 6.0 –
200–208 Leukaemia and lymphoma 8 12.4 0.2 0.1 to 0.4 5
200 Non-Hodgkin’s disease 3 4.9 0.2 0.03 to 0.4 2
201 Hodgkin’s disease 0 1.0 – – –
204–208 Leukaemia 5 4.1 1.5 0.5 to 3.5 3
See Methods section for estimating RR. Obs, observed, exp, expected.
Table 3 Gender specific cancer risks for sites other than breast and ovary in BRCA2
mutation carriers
ICD Location Obs Exp RR 95% CI Pa (n)
Male All 139 117.7 1.4 1.1 to 1.6 57
146–149 Pharynx 3 0.8 6.7 1.4 to 19.7 1
150–159 Digestive system 37 29.6 1.5 1.1 to 2.1 17
155 Liver 4 0.7 11.1 3.0 to 28.5 2
157 Pancreas 11 2.5 7.8 3.9 to 14.0 6
170 Bones 2 0.3 15.0 1.7 to 54.3 1
179–189 Urogenital system 34 25.2 1.7 1.2 to 2.4 14
185 Prostate 24 13.6 2.5 1.6 to 3.8 7
Female All 60 82.3 0.3 0.3 to 0.4 27
157 Pancreas 4 1.9 3.7 1.0 to 9.4 1
See Methods section for estimating RR. Obs, observed, exp, expected.
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due to prostate cancer, the true SMR for prostate cancer will
be somewhat lower. Furthermore, in a comparable Dutch
study among BRCA1 mutation carriers with equal potential
for detecting bias, a decreased RR for prostate cancer was
found.29 Based on these results, we concluded that the
reported risk elevation of prostate cancer could not be fully
explained by screening.
Pancreatic cancer has also been observed as a feature of the
BRCA2 spectrum in several other studies.30–36 In a series of 26
European families with at least two first degree relatives with
a histologically confirmed diagnosis of pancreatic ductal
adenocarcinoma, three pathogenic BRCA2 mutations were
observed, and two families harboured an unclassified variant
of the BRCA2 gene.37 The median age at diagnosis of pancreatic
cancer in this series was 60 years and the youngest patient
identified with pancreatic cancer was 33 years. Remarkably, a
case of pancreatic cancer in our study cohort occurred in a
child of 9 years old. Although this child was not a typed
carrier, we think it is quite likely that this event was caused by
a pathogenic BRCA2 mutation (3038delAA), which was found
in a first degree relative of the girl. In this respect, it is of
interest that compound heterozygosity for BRCA2 germline
mutations has been reported in children with Fanconi anaemia
and medulloblastoma.38 Families with a BRCA2 mutation
outside the OCCR region tended to have a higher risk for
pancreas cancer (RR 8.9; 95% CI 3.6 to 18.3). Our results are in
contrast with one earlier report by Risch et al, who found that
families with a BRCA2 mutation inside the OCCR region
tended to have a higher risk for pancreatic cancer.39
Similar to BCLC, we found an increased risk for liver
cancer. However, liver cancer is an uncertain diagnosis, when
relying upon reports given by family members. In our series,
only a minority (two of five) was confirmed by pathology
records and it is quite possible that the unconfirmed liver
cancers were metastases of breast/ovarian or other cancers, as
the liver is a common site for metastasis of breast/ovarian
cancer. No significant excess was observed when we based
our estimate on confirmed cases only (data not shown). It is
also possible, however, that some of these unconfirmed liver
cancers were bile duct cancers as reported to occur in excess
by the BCLC study.9 The same remark could be made about
brain cancers, also known as sites for metastases of breast/
ovarian tumours. It was only possible to confirm one case
pathologically.
One earlier study reported an increased risk for colon
cancer in BRCA2 families (RR 2.5; 95% CI 1.0 to 6.3).39 The
BCLC study concerning BRCA2 mutation families reported a
slight but non-significant increase of the risk for colon and
rectum cancer only. In our overall analyses, the RR for cancer
of the digestive tract was slightly and significantly increased,
which could be explained by slight excesses of cancers of the
colon and stomach and a greater excess of cancers of the
pancreas and liver. The slight increase in colon cancer risk
must be considered in the light of a marked decrease in the
number of rectal cancers. It is possible that some rectal
cancers were inaccurately reported by family members as
being from the colon. When the two sites were considered
together, the RR was even lower than unity in our data. This
is in line with observations in two population based
studies.40 41
We observed a significantly increased risk for cancer of the
pharynx (RR 7.3; 95% CI 2.0–18.6), based on two confirmed
and two unconfirmed cases. In the study of Easton et al,
based on two families from Ireland and from Utah in the
USA, no cancers of the pharynx were found. However, an
increased RR of 7.7 was found for laryngeal cancers, based on
two possible mutation carriers.42 It was unclear whether these
cases were pathologically confirmed. We could not confirm
an excess of larynx cancers in our study. Three cases were
found, of which two could be pathologically confirmed.
Nevertheless, it is conceivable that the reported cancers of the
‘‘throat’’ were inaccurately diagnosed. These may have been a
variety of cancers in the ear, nose, and throat area, including
oesophageal cancer and possibly also laryngeal cancers.
Significant increases for laryngeal cancer and pharyngeal
cancer as reported by Easton et al and in our study,
respectively, may suggest an increased risk for tumours of
the throat area in BRCA2 families.
Table 4 Age specific cancer risks in BRCA2 mutation carriers
Location
,65 years of age >65 years of age
Obs Exp RR 95% CI Obs Exp RR 95% CI
All cancers 95 29.4 5.5 0.7 to 1.4 104 170.5 0.2 0.2 to 0.3
Pharynx 2 0.3 15.7 1.8 to 56.6 2 0.8 4.2 0.5 to 14.9
Colon 8 1.8 8.0 3.4 to 15.7 12 14.7 0.6 0.3 to 1.1
Pancreas 8 0.4 37.1 16.0 to 73.1 7 4.0 2.5 1.0 to 5.2
Prostate* 12 2.7 8.0 4.1 to 14.0 12 10.9 1.2 0.6 to 2.1
See Methods section for estimating RR. *Prostate cancer risk estimated before and below 73 years of age. For all
presented cancer sites, p for difference is ,0.001.
Table 5 Estimated RRs for BRCA2 mutation carriers by ovarian cancer cluster region
(OCCR)
Location
Inside OCCR* Outside OCCR*
Obs Exp RR 95% CI Obs Exp RR 95% CI
All cancers 130 135.6 0.9 0.8 to 1.1 69 64.4 1.1 0.9 to 1.4
Buccal cavity and
pharynx
4 2.4 2.3 0.6 to 5.8 2 1.2 2.4 0.3 to 8.7
Liver 2 0.6 5.3 0.6 to 9.3 3 0.3 19 3.9 to 55.5
Pancreas 8 3.0 4.4 1.9 to 8.7 7 1.4 8.9 3.6 to 18.3
Uterus 3 2.0 2.0 0.4 to 5.8 3 1.4 3.2 0.7 to 9.3
Prostate 14 9.2 2.0 1.1 to 3.4 10 4.4 3.6 1.7 to 6.6
*OCCR is the ovarian cancer cluster region with nucleotide boundaries between 3035 and 6629 (Gather et al,
1997).
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In contrast with the earlier reported study of the BCLC, we
could not confirm the observed significantly increased risks
of gallbladder and bile duct cancer, stomach cancer and
malignant melanoma.9 Unfortunately, only general informa-
tion is given in the BCLC study about the percentage of
confirmed tumours—that is, 53%; no detailed information
was available about the degree of pathological confirmation
of these specific cancers, which showed a significant excess.
The authors suggested in the discussion section that some of
the excess of stomach cancer could be attributed to
misclassification of ovarian cancer, as the observed RR was
somewhat higher in female than in male carriers (4.2 v 2.1)
and some of cancers of the gallbladder and bile ducts might
have been misclassified pancreatic cancers.
The BCLC study also showed an increase for malignant
melanoma. In our cohort, however, the risk of melanoma was
significantly decreased. Based on two large breast cancer
families linked to BRCA2, suggestive evidence was provided
that the risk of uveal melanoma is elevated in mutation
carriers.42 However, in a recent study of 385 patients with
uveal melanoma, no pathogenic BRCA2 mutation could be
detected.43
Like liver cancer, cancer of the bone is a difficult diagnosis.
Most of the reported tumours were unconfirmed and such
findings might be a distant metastasis of breast cancer.
However, increased risks for these tumours were still found
after excluding all female individuals with a history of breast
and ovarian cancer (liver cancer: RR 10.5; 95% CI 3.4 to 24.5;
brain: 2.9; 0.8–7.4; bone: 8.8; 1.1 to 31.6). This indicated that
the influence of metastasised cancers on the reported RRs of
liver, brain, and bone is probably small.
It is notable that we observed a significantly decreased risk
of lung cancer in BRCA2 carriers, both in males and females
(data for genders not shown). A likely explanation of the low
lung cancer risk in BRCA2 carriers is that members of breast/
ovarian cancer families smoke less than the general popula-
tion, because they are more aware of lifestyle factors that
increase cancer risk. In the earlier reported BCLC study the
observed RR for lung cancer was not decreased (RR 1.04; 95%
CI 0.62 to 1.73).
In the gender specific analyses in female subjects only, a
marginally significant increase could be observed for pan-
creatic cancer (RR 3.7; 95% CI 1.0 to 9.4). In carriers of a
BRCA1 mutation, the overall increased risk of cancer at sites
other than breast and ovary is small and is observed in
women but generally not in men.10 11
As we used a retrospective design, we were concerned that
affected individuals might have been inclined to opt for DNA
testing more often than their non-affected relatives, which
would lead to overestimation of cancer risk using typed
carriers. Therefore, we used a novel approach for selecting a
study cohort of family members with a 50% prior probability
of being a carrier, irrespective of their known carrier status.
Although this method meant that we had to reduce our
available study population, which means loss of statistical
power, we minimised testing bias.
An obvious concern in this study is that the observed
excess cancer risk in carriers may be the result of selection of
families for the occurrence of other cancers. Therefore, we
examined the overall risk in families with a strong history
(three or more breast cancers before 60 years of age, any
ovarian cancer or male breast cancer) and compared this with
the RRs in families with a less strong family history. The RR
for all cancers other than breast and ovary in families with a
strong family history was somewhat higher than in families
with a weaker family history, suggesting that any ascertain-
ment bias is likely to be small (data not shown).
In conclusion, we found that male BRCA2 carriers are at
increased risk for cancer of the prostate, pancreas, throat and
possibly bone. For clinical practice, it is important to consider
also absolute risks and mortality due to the cancers observed.
The observed risks for prostate cancer may warrant con-
sideration of male carriers as candidates for inclusion in high
risk prostate screening studies. However, screening for
prostate cancer is controversial. Important disadvantages
include potential overdiagnosis and treatment, with treat-
ment related complications, while a reduction of prostate
cancer mortality has not been convincingly demonstrated.
Nevertheless, early radical treatment instead of watchful
waiting, notably among patients with a life expectancy
exceeding 15 years, might give survival benefit.44–46 For all
these reasons, surveillance of healthy men from BRCA2
families with an increased risk for developing prostate cancer
should only be initiated in a research setting.
APPENDIX
During follow up carriers were censored more frequently
than non-carriers and died on average earlier than the non-
carriers. Therefore, we calculated the RR for carriers by the
following formula:
where w=weight, n=number of women at start of
follow-up, O=observed, E=expected, RR= relative risk of
cancer other than breast and ovarian cancer, a=proportion
of total mortality within 20 years from a breast cancer
diagnosis, attributed to breast cancer: 85%*, b=proportion of
total mortality after 20 years from a breast cancer diagnosis,
attributed to breast cancer: 50%*, c=proportion of total
mortality within 15 years from an ovarian cancer diagnosis,
attributed to ovarian cancer: 100%*, d=number of follow up
periods in the analysis, m= incidence of other cancers,
n=mortality within 20 years from breast cancer diagnosis,
o=mortality after 20 years from breast cancer diagnosis,
p=mortality within 15 years from ovarian cancer diagnosis.
In fact, the probability of being a carrier at start of follow
up of the analysed cohort was slightly lower than 50%, as 105
members of the selected cohort were not eligible for follow
up: 79 had died and 26 had another tumour before 1960. It is
likely that the probability of being a carrier was more than
50% among this excluded group, and less than 50% in those
of their siblings (n=202) who were included in the analysed
cohort. As we assumed an overall probability of 50% in the
analysed cohort at start of follow up, the weights and the RRs
are slightly conservative estimates (data not shown).
Table 6 Estimated cumulative risks for pancreas and
prostate cancer in BRCA2 mutation carriers by sex and
age
Age
category
(years)
Pancreas
ProstateMen Women
Risk * 95% CI Risk 95% CI Risk 95% CI
,30 0 0 0 0 0 0
30–40 0 0 0 0 to 0.3 0 0
40–50 0.3 0 to 1.4 0.2 0 to 0.7 0.1 0 to 0.5
50–60 1.2 0 to 3.2 0.5 0 to 1.5 0.8 0 to 2.3
60–70 4.1 1.0 to 7.3 1.4 0 to 3.4 5.2 1.7 to 8.7
70–80 6.9 3.8 to 10 2.8 0.9 to 4.7 17.3 12.5 to 22
*Cumulative risk as the probability of an individual being diagnosed with
cancer by age t, conditional upon survival through all preceding age
periods (%).
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* Based on large breast cancer cohort identified from two
Dutch cancer clinics (MJ Hooning, FE van Leeuwen, personal
communication).
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